Curative-intent radiotherapy for glottic carcinoma in situ

Area of Science:

• Oncology
• Radiotherapy
• Laryngeal Cancer Research

Background:

• Glottic carcinoma in situ (CIS) is a laryngeal malignancy.
• Previous transoral excision may lead to recurrent or persistent CIS.
• Curative radiotherapy (RT) is an alternative treatment modality.

Purpose of the Study:

• To update treatment experience with curative radiotherapy (RT) for glottic carcinoma in situ (CIS).
• To evaluate the efficacy and safety of RT for glottic CIS.
• To assess outcomes for patients with previously untreated or recurrent glottic CIS.

Main Methods:

• Fifty patients with glottic CIS received continuous-course RT with once-daily fractionation.
• Median total RT dose was 63.0 Gy; median dose per fraction was 2.25 Gy.
• Median follow-up was 9.6 years.

Main Results:

• Five-year local control was 91%, with ultimate local control (including salvage) reaching 100%.
• Ultimate local control with larynx preservation was 93%.
• No severe complications were observed, and survival rates were high (cause-specific 100%, overall 81%).

Conclusions:

• Radiotherapy (RT) is an excellent treatment for glottic carcinoma in situ (CIS).
• RT is effective for recurrent CIS after transoral excision.
• RT is a suitable option for patients with untreated CIS unsuitable for partial laryngectomy.